

## Crossject: result of votes at the Combined General Meeting of 25 June 2020

Dijon, 29 June 2020

**CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing a portfolio of innovative combined drugs for use in emergency situations,** held its Annual Combined General Meeting behind closed doors on 25 June 2020 at the company's headquarters, under the chairmanship of Philippe Monnot, Chairman of the Management Board.

The bureau also consisted of two scrutineers appointed by the Management Board: Ms Castano and Mr Garret. Philippe Lafitte was appointed secretary of the bureau.

The bureau noted, on the basis of postal votes and proxies received, that the participating shareholders represented 33.70% of the shares forming the capital and having voting rights, and as such that the Meeting was validly constituted.

The Management Board provided answers to written questions asked by a shareholder who had provided his account registration certificate. The questions and answers have been posted on the Crossject website in the "General Meeting" section: <https://www.crossject.com/>.

The Meeting approved all the resolutions submitted to it, including in particular:

- For those submitted to the Ordinary General Meeting:
  - o the appropriation of the result for the 2019 financial year and the partial clearance of the loss on the unavailable reserves,
  - o the renewal of PricewaterhouseCoopers Audit as statutory auditor,
  - o the non-renewal and non-replacement of Etienne Boris as alternate auditor,
  - o the recognition of the reconstitution of the company's shareholders' equity,
  - o the authorisation to be granted to the Management Board to allow the company to buy back its own shares under the share buyback programme.
- For those submitted to the Extraordinary General Meeting:
  - o the renewal of financial delegations,
  - o the amendment of Article 23 of the Articles of Association in order to allow certain Board decisions to be taken by written consultation,



- the amendment of Article 23 of the Articles of Association on the modalities for giving proxy within the Board,
- the alignment of the Articles of Association with the regulations in force.

The detailed results of the votes on the resolutions submitted to the Combined General Meeting are available on the company's website in the "General Meeting" section <https://www.crossject.com/>.

**Next release:** 18 September 2020 (after trading): First-half 2020 results

### Contacts:

**Crossject**  
Patrick Alexandre  
[info@crossject.com](mailto:info@crossject.com)

**Investor relations**  
**CIC Market Solutions**  
Catherine Couanau +33 (0)1 53 48 81 97  
[catherine.couanau@cic.fr](mailto:catherine.couanau@cic.fr)

**Press relations**  
**Buzz & Compagnie**  
Mélanie Voisard +33 (0)3 80 43 54 89  
[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)  
Christelle Distinguin +33 (0)3 80 43 54 89  
[christelle.distinguin@buzzetcompagnie.com](mailto:christelle.distinguin@buzzetcompagnie.com)

### About CROSSJECT • [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.



## RESULT OF THE VOTE ON THE RESOLUTIONS

(decree 2010-684 of 23 June 2010)

Number of shares comprising the company's share capital:	23,900,884
Number of shares with voting rights:	22,934,136
Number of shareholders present or represented at the Meeting:	24
Number of votes of shareholders present or represented at the meeting:	10,214,371

Resolution number	Total votes cast	Number of shares represented by votes cast	Proportion of capital represented by votes cast	For		Against		Result	Abstention
				Number of votes	%	Number of votes	%		Number of votes
1	10,214,371	8,004,365	33.49% of capital	10,153,216	99.40	61,155	0.60	Adopted	0
2	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0
3	10,192,371	7,982,365	33.4% of capital	9,480,207	93.01	712,164	6.99	Adopted	0
4	10,214,371	8,004,365	33.49% of capital	9,623,027	94.21	591,344	5.79	Adopted	0
5	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0
6	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0
7	10,214,371	8,004,365	33.49% of capital	10,153,216	99.40	61,155	0.60	Adopted	0
8	10,214,371	8,004,365	33.49% of capital	10,153,216	99.40	61,155	0.60	Adopted	0
9	10,214,371	8,004,365	33.49% of capital	8,425,095	82.48	1,789,276	17.52	Adopted	0
10	10,214,371	8,004,365	33.49% of capital	8,317,554	81.43	1,896,817	18.57	Adopted	0
11	10,192,371	7,982,365	33.4% of capital	8,295,554	81.39	1,896,817	18.61	Adopted	22,000
12	10,214,371	8,004,365	33.49% of capital	9,352,207	91.56	862,164	8.44	Adopted	0
13	10,214,371	8,004,365	33.49% of capital	10,064,371	98.53	150,000	1.47	Adopted	0
14	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0
15	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0
16	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0
17	10,214,371	8,004,365	33.49% of capital	9,563,362	93.63	651,009	6.37	Adopted	0
18	10,214,371	8,004,365	33.49% of capital	10,214,371	100.00	0	0	Adopted	0